Novartis Drug Pipeline

Novartis maintains a substantial portfolio of clinical programs, with 236 active trials and a total of 2065 trials registered since 2008. These active trials span from Phase 1 through Phase 4, with 61, 93, 89, and 24 trials respectively. The portfolio covers 18 therapeutic areas, but is heavily concentrated in Oncology, which accounts for 56% of active programs (132 trials). Within Oncology, the leading indications by active trial count are Prostate Cancer (22 active, 3 in Phase 3), Advanced Solid Tumors (19 active, 3 in Phase 3), Non-Small Cell Lung Cancer (13 active, 1 in Phase 3), Breast Cancer (11 active, 4 in Phase 3), and Chronic Myelogenous Leukemia (7 active, 2 in Phase 3). Beyond Oncology, other therapeutic areas with notable activity include Central Nervous System (21 active trials), Immunology (16 active trials), Rare Diseases (12 active trials), Cardiovascular (8 active trials), and Metabolic Diseases (5 active trials). The relatively large number of Phase 3 trials across multiple indications suggests a pipeline with potential near-term catalysts.